aap successfully places a 10% capital increase from authorized capital at
EUR 1.10 with exclusion of subscription rights

EQS-News: aap Implantate AG / Key word(s): Capital Increase
aap successfully places a 10% capital increase from authorized capital at
EUR 1.10 with exclusion of subscription rights

19.04.2024 / 07:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

* The premium to the current share price of EUR 0.8 amounted to 37.5%

  * The cash inflow will strengthen the company's own resources for the
    ongoing human clinical trial of the innovative antibacterial implant
    technology

aap Implantate AG ("aap" or "Company") successfully completed the 10%
capital increase announced on March 18, 2024 with exclusion of subscription
rights at a placement price of EUR 1.10, which corresponds to a premium of
37.5%. The company will thus receive liquid funds of EUR 986,311.70. This
cash inflow will strengthen the company's own resources for the ongoing
human clinical trial of the innovative antibacterial implant technology. The
investors have also already signaled that they will provide further funds if
business develops positively.




---------------------------------------------------------------------------------------------------

aap Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market -
All German stock exchanges -

About aap Implantate AG

aap Implantate AG is a globally active medical technology company based in
Berlin, Germany. The company develops, produces and markets products for
traumatology. In addition to the innovative LOQTEQ® anatomical plate system,
the IP-protected portfolio includes a wide range of cannulated screws. In
addition, aap Implantate AG has an innovation pipeline with promising
development projects such as antibacterial silver coating technology and
magnesium-based implants. These technologies address critical problems in
traumatology that have not yet been adequately solved. In Germany, aap
Implantate AG sells its products directly to hospitals, purchasing groups
and group clinics, while internationally it primarily uses a broad network
of distributors in around 25 countries. In the United States, the company
relies on a sales strategy via distribution agents through its subsidiary
aap Implants Inc. The aap Implantate AG share is listed in the General
Standard of the Frankfurt Stock Exchange (XETRA: AAQ.DE). For further
information, please visit our website at www.aap.de.

The figures presented in this press release may be subject to technical
rounding differences that do not affect the overall picture.

Forward-looking statements

This release may contain forward-looking statements that are based on the
current expectations, assumptions and forecasts of the Executive Board and
information currently available to it. The forward-looking statements are
not to be understood as guarantees of the future developments and results
mentioned therein. Various known and unknown risks, uncertainties and other
factors could lead to material differences between the actual results,
financial situation, development or performance of the company and the
estimates given here. These factors include those that aap has described in
published reports. Forward-looking statements therefore speak only as of the
date on which they are made. We assume no obligation to update the
forward-looking statements made in this release or to conform them to future
events or developments.

If you have any questions, please contact:

aap Implantate AG; Rubino Di Girolamo, Chairman of the Management Board/
CEO, Lorenzweg 5; 12099 Berlin

Phone: +49 (0)30 75019 - 170; Fax: +49 (0)30 75019 - 290; Email:
r.digirolamo@aap.de


---------------------------------------------------------------------------

19.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        aap Implantate AG
                   Lorenzweg 5
                   12099 Berlin
                   Germany
   Phone:          +49 (0) 30 75 019-0
   Fax:            +49 (0) 30 75 019-111
   E-mail:         info@aap.de
   Internet:       www.aap.de
   ISIN:           DE000A3H2101
   WKN:            A3H210
   Listed:         Regulated Market in Frankfurt (General Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Hamburg, Munich, Stuttgart, Tradegate Exchange
   EQS News ID:    1884191

End of News EQS News Service
---------------------------------------------------------------------------

1884191 19.04.2024 CET/CEST